Wednesday, March 04, 2026 | Ramadan 14, 1447 H
clear sky
weather
OMAN
22°C / 22°C
EDITOR IN CHIEF- ABDULLAH BIN SALIM AL SHUEILI
x
19,000 Middle East flights cancelled since Feb 28
Sayyid Badr renews call for immediate ceasefire
Iran targets the energy industry
Day 4: Markets tumble as energy supply is disrupted
HM receives two phone calls
India says developments in the Gulf cause 'great anxiety'
Oman intercepts drones over Dhofar, no casualties reported
Israel launches massive campaign in Lebanon
Oman Air announces flight suspensions for March 4-6
Fuel tanks at Port of Duqm attacked by drones, no casualties

Australian track star Bol cleared of doping

Peter Bol1
Peter Bol1
minus
plus

SYDNEY: A doping investigation into Australian Olympic 800m runner Peter Bol was dropped on Tuesday, with the middle-distance star calling it "a dream come true".


Bol, who narrowly missed bronze when he finished fourth at the 2020 Tokyo Olympics, returned a positive result for performance-enhancing Erythropoietin Receptor Agonists (EPO) in January.


He was suspended from all competition, but a later analysis of his B-sample returned an "atypical finding", meaning it did not confirm the original test.


The Sudan-born athlete, who always claimed innocence, has now been cleared, with further testing at a World Anti-Doping Agency-accredited laboratory confirming a negative result


"As a result, Sport Integrity Australia has taken the decision not to progress an anti-doping rule violation for this sample," the anti-doping agency said. "The investigation into this sample is finalised."


Peter Bol2
Peter Bol2


Bol said he had been "exonerated" and would now focus on the World Athletics Championships in Hungary later this month.


"It was a false positive like I have said all along," he said.


"The news from Sport Integrity Australia today was a dream come true. No one should ever experience what I have gone through this year."


Wada said it was satisfied that Sport Integrity Australia followed all applicable processes, but would conduct a review nevertheless.


"While we have no reason to question the validity of the analytical method used for recombinant EPO, Wada will assess the current review process in light of the particularities of this case," it said. — AFP


SHARE ARTICLE
arrow up
home icon